Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes.

[1]  U. Rüther,et al.  Ftl, a novel gene related to ubiquitin-conjugating enzymes, is deleted in the Fused toes mouse mutation , 1997, Mammalian Genome.

[2]  G. Rayan.  Nonoperative treatment of Dupuytren's disease. , 2008, The Journal of hand surgery.

[3]  A. Kudo,et al.  Impaired capsule formation of tumors in periostin-null mice. , 2008, Biochemical and biophysical research communications.

[4]  J. Stanley,et al.  Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. , 2008, The Journal of hand surgery.

[5]  R. Geffers,et al.  Identification of unique gene expression patterns within different lesional sites of keloids , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[6]  J. Foidart,et al.  Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. , 2008, Biochimie.

[7]  A. Leclerc,et al.  Dupuytren's disease: personal factors and occupational exposure. , 2008, American journal of industrial medicine.

[8]  H. Inoue,et al.  Role of alternative splicing of periostin in human bladder carcinogenesis. , 2008, International journal of oncology.

[9]  W. LaFramboise,et al.  BMC Medical Genomics BioMed Central , 2008 .

[10]  F. Brasseur,et al.  Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells , 2007, Molecular Cancer.

[11]  D. McGrouther,et al.  Assessment of clinical severity in Dupuytren's disease. , 2007, British journal of hospital medicine.

[12]  Wen-hao Tang,et al.  Expression of periostin and its clinicopathological relevance in gastric cancer. , 2007, World journal of gastroenterology.

[13]  K. Midwood,et al.  Regulation of fibroblast migration by tenascin-C. , 2007, Biochemical Society transactions.

[14]  F. Colland,et al.  The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor , 2007, The Journal of cell biology.

[15]  Y. Kudo,et al.  Periostin: novel diagnostic and therapeutic target for cancer. , 2007, Histology and histopathology.

[16]  E. Keystone,et al.  Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity , 2007, Genes and Immunity.

[17]  Tomas Mitkus,et al.  Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. , 2007, Gastroenterology.

[18]  B. Law,et al.  Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. , 2007, Cancer research.

[19]  S. Donell,et al.  A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. , 2007, The Journal of hand surgery.

[20]  T. Ørntoft,et al.  Molecular Profiling of ADAM12 in Human Bladder Cancer , 2006, Clinical Cancer Research.

[21]  Melanie M. Choe,et al.  Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[22]  S. Calza,et al.  Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. , 2006, Gynecologic oncology.

[23]  Y. Kudo,et al.  Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer , 2006, British Journal of Cancer.

[24]  J J Dias,et al.  Dupuytren’s Contracture: An Audit of the Outcomes of Surgery , 2006, Journal of hand surgery.

[25]  Yan Wu,et al.  Wnt expression is not correlated with β-catenin dysregulation in Dupuytren's Disease , 2006, Journal of Negative Results in BioMedicine.

[26]  D. Brenner,et al.  Mechanisms of alcohol‐induced hepatic fibrosis: A summary of the Ron Thurman Symposium , 2006, Hepatology.

[27]  M. Post,et al.  Iroquois genes influence proximo-distal morphogenesis during rat lung development. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[28]  S. John,et al.  The heritability of Dupuytren's disease: familial aggregation and its clinical significance. , 2006, The Journal of hand surgery.

[29]  M. Longaker,et al.  Expression of a novel gene, MafB, in Dupuytren's disease. , 2006, The Journal of hand surgery.

[30]  P. Barnes,et al.  Treatment of airway mucus hypersecretion , 2006, Annals of medicine.

[31]  A Bayat,et al.  Management of Dupuytren's disease--clear advice for an elusive condition. , 2006, Annals of the Royal College of Surgeons of England.

[32]  K. Hemminki,et al.  Polymorphisms in the KDR and POSTN Genes: Association with Breast Cancer Susceptibility and Prognosis , 2006, Breast Cancer Research and Treatment.

[33]  H. Folkesson,et al.  Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling. , 2006, American journal of physiology. Heart and circulatory physiology.

[34]  Joshua S. Yuan,et al.  Real-time PCR Statistics , 2006 .

[35]  G. Baffet,et al.  Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. , 2005, Journal of hepatology.

[36]  Y. Baruch,et al.  Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. , 2005, Journal of hepatology.

[37]  A. Harris,et al.  Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer , 2005, British Journal of Cancer.

[38]  M. Hiroe,et al.  Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. , 2005, The American journal of pathology.

[39]  M. Hart,et al.  Clinical associations of Dupuytren’s disease , 2005, Postgraduate Medical Journal.

[40]  P. Kronqvist,et al.  A role for ADAM12 in breast tumor progression and stromal cell apoptosis. , 2005, Cancer research.

[41]  K. Olczyk,et al.  Alterations in the extracellular matrix proteoglycan profile in Dupuytren's contracture affect the palmar fascia. , 2005, Journal of biochemistry.

[42]  A. Sandford,et al.  Selection of reference genes for gene expression studies in human neutrophils by real-time PCR , 2005, BMC Molecular Biology.

[43]  Erming Tian,et al.  Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy , 2004, International journal of cancer.

[44]  F. Rödel,et al.  Transforming growth factor beta 1 dependent regulation of Tenascin-C in radiation impaired wound healing. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  A. Qian,et al.  Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. , 2004, Urology.

[46]  J. S. Watson,et al.  Genetic Susceptibility to Dupuytren Disease: Association of Zf9 Transcription Factor Gene , 2003, Plastic and reconstructive surgery.

[47]  J. S. Watson,et al.  Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. , 2003, British journal of plastic surgery.

[48]  K. Fujimoto,et al.  Anti-membrane-bound transferrin-like protein antibodies induce cell-shape change and chondrocyte differentiation in the presence or absence of concanavalin A , 2003, Journal of Cell Science.

[49]  G. Baffet,et al.  ADAM12 in human liver cancers: TGF‐β‐regulated expression in stellate cells is associated with matrix remodeling , 2003, Hepatology.

[50]  W. Graham,et al.  Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. , 2002, Plastic and reconstructive surgery.

[51]  G Vallancien,et al.  Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns , 2002, British Journal of Cancer.

[52]  G. Ehrlich,et al.  Mapping a gene for dupuytren contracture in two Swedish families. , 2002 .

[53]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[54]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[55]  A. Gressner,et al.  LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. , 2001, The Biochemical journal.

[56]  A. Moorman,et al.  Gene and cluster-specific expression of the Iroquois family members during mouse development , 2001, Mechanisms of Development.

[57]  J. D. Saar,et al.  Dupuytren's disease: an overview. , 2000, Plastic and reconstructive surgery.

[58]  J. Lefaix,et al.  Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation. , 1998, Radiation research.

[59]  S. Klahr,et al.  Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. , 1997, Kidney international. Supplement.

[60]  P. Greenwel,et al.  Up‐regulation of type I procollagen C‐proteinase enhancer protein messenger RNA in rats with CCl4‐induced liver fibrosis , 1997, Hepatology.

[61]  J. Hogg,et al.  Proteoglycan deposition in pulmonary fibrosis. , 1996, American journal of respiratory and critical care medicine.

[62]  T. Dragani,et al.  Downexpression of aldehyde dehydrogenase 1 in murine lung tumors , 1996, Molecular carcinogenesis.

[63]  L. Hurst,et al.  The role of transforming growth factor beta in Dupuytren's disease. , 1996, The Journal of hand surgery.

[64]  M. Gariboldi,et al.  The daunorubicin-binding protein of Mr 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines. , 1994, Molecular pharmacology.

[65]  J. Büttner.  Reference materials and reference methods in laboratory medicine: a challenge to international cooperation. , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[66]  H. Kosmehl,et al.  Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. , 1994, Pathobiology : journal of immunopathology, molecular and cellular biology.

[67]  H. Erickson.  Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. , 1993, Current opinion in cell biology.

[68]  A. Gressner,et al.  Differential expression of keratan sulphate proteoglycans fibromodulin, lumican and aggrecan in normal and fibrotic rat liver , 1992, FEBS letters.

[69]  K. Remberger,et al.  Palmar fibromatosis-"Dupuytren's contracture". A comparison of light electron and immunofluorescence microscopic findings. , 1979, Pathology, research and practice.

[70]  J. J. Niebauer,et al.  Treatment of Dupuytren's contracture. Long-term results after fasciotomy and fascial excision. , 1976, The Journal of bone and joint surgery. American volume.

[71]  G. Gabbiani,et al.  Dupuytren's contracture: fibroblast contraction? An ultrastructural study. , 1972, The American journal of pathology.